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Abstract
Background: A number of expression systems have been developed where transgene expression
can be regulated. They all have specific characteristics making them more suitable for certain
applications than for others. Since some applications require the regulation of several genes, there
is a need for a variety of independent yet compatible systems.
Results: We have used the regulatory mechanisms of bacterial operons (cmt and cym) to regulate
gene expression in mammalian cells using three different strategies. In the repressor configuration,
regulation is mediated by the binding of the repressor (CymR) to the operator site (CuO), placed
downstream of a strong constitutive promoter. Addition of cumate, a small molecule, relieves the
repression. In the transactivator configuration, a chimaeric transactivator (cTA) protein, formed by
the fusion of CymR with the activation domain of VP16, is able to activate transcription when
bound to multiple copies of CuO, placed upstream of the CMV minimal promoter. Cumate
addition abrogates DNA binding and therefore transactivation by cTA. Finally, an adenoviral library
of cTA mutants was screened to identify a reverse cumate activator (rcTA), which activates
transcription in the presence rather than the absence of cumate.
Conclusion: We report the generation of a new versatile inducible expression system.
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Background
Tightly controlled inducible expression of transfected
genes greatly aids functional studies in relevant biological
systems. The ability to regulate both the level and the
duration of expression allows the study of proteins whose
constitutive expression might not be tolerated by the cell.
A number of inducible systems endogenous to mamma-
lian cells involving regulation by heavy-metals [1-3], ster-
oid hormones [4-6], heat shock [7] and other reagents
have been developed [8,9]. However, there are limitations
with these inducible mammalian promoters such as
"leakiness" of the "off" state and pleiotropic effects of
inducers (heat shock, heavy metals, glucocorticoids etc.)
[1,6]. The use of insect hormones (ecdysone) has been
proposed in an attempt to reduce the interference with
cellular processes in mammalian cells [10]. Another ele-
gant system uses rapamycin as the inducer [11] but the
role of rapamycin as an immunosuppressant was a major
limitation to its use in vivo and therefore it was necessary
to find a biologically inert compound [12] for the control
of gene expression.
As an alternative, the control elements from the tetracy-
cline resistance operon from E. coli were harnessed for
gene regulation in mammalian cells. In its original config-
uration, an artificial promoter was rendered responsive to
a chimaeric transactivator (tTA, composed of the repressor
(TetR) fused to the VP16 activation domain), by linking
the seven repeats of the Tet operator sequence to the min-
imal promoter elements of the human cytomegalovirus
immediate early gene (CMV-IE) promoter. Transcription
from the Tet promoter is activated by tTA whose binding
to DNA is inhibited by tetracycline or by the rtTA whose
binding to DNA is induced by tetracycline. The specificity
of the interaction of TetR with the operator sequence, the
large induction levels, the extensive studies on the safety
of tetracycline and its high affinity for the TetR made this
an attractive system [13]. Since the original report of the
Tet switch, a number of modifications have been
reported. These include the use of a repressor to block
basal transcription [14] and the fusion of a repression
domain to the TetR to generate a silencer molecule
[15,16]. Furthermore, Hofmann et al. [17] have shown
that use of a modified mouse mammary tumor virus pro-
moter (MMTV) instead of the minimal CMV promoter in
the Tet switch results in a lower basal activity in the
absence of transactivator. Baron et al. [18] reported that
cells better tolerate a modified tTA, wherein the VP16 acti-
vation domain is truncated. A first generation reverse
mutant was isolated in a bacterial screen and more
recently a screen in Saccharomyces cerevisiae has led to the
identification of rtTA molecules with improved regulatory
properties (rtTA2-S2 and rtTA2-M2). These and other 
modifications have made the Tet switch the most widely
used inducible system in mammalian cells [19].
However, there is a need for additional systems for the
control of gene expression in mammalian cells as evi-
denced by several recent reports of new systems [20-23]. It
is not only desirable but necessary to have a wide variety
of regulatory systems since an increasing number of appli-
cations benefit from the possibility of controlling simulta-
neously but independently, the expression of several
genes [9]. Others may require generating combinatorial
control systems that would enable, for instance, the func-
tional characterization of gene products involved in cas-
cades [24] such as signal transduction or control of
programmed cell death. All of these require the use of sev-
eral compatible gene regulation systems. Thus, following
the paradigm of the TetR, other microbial repressors regu-
lating antibiotic resistance operons, have been developed
by Fussenegger and co-workers [25,26]. Both the streto-
gramin- and macrolide-based gene switches have been
shown to be efficient in vitro and in vivo and fully compat-
ible with the Tet switch. Combination of these gene
switches now allows for sophisticated multilevel gene reg-
ulation in mammalian cells [27].
The bacterial repressor we have chosen to use as a base for
developing our system controls expression from the p-cmt
and p-cym  operon in Pseudomonas putida [28]. It has a
deduced molecular weight of 23,324 daltons. By sequence
comparison, it has been proposed that the DNA-binding
domain is located in the N-terminus of the protein and
has the characteristics of a helix-turn-helix motif. DNA
sequence analysis of the promoter regions (P1 and P2)
(Fig. 1A) of the p-cym and p-cmt operons, reveal an imper-
fect and a perfect inverted repeat (in bold; Fig 1A) respec-
tively with characteristics of a binding site for a helix turn
helix DNA-binding domain [28]. The imperfect repeat is
located between the promoter and the beginning of the
first gene in the p-cymene degradative pathway. This gene
codes for cumic alcohol dehydrogenase, which is respon-
sible for the conversion of p-cymene to p-cumate. A simi-
lar sequence is found in the promoter region of the Da
gene, which is first in the degradative pathway of p-
cumate. Since CymR regulates expression from the p-cym
and p-cmt operons, both sequences have been defined as
putative operator sequences (CuO).
We have exploited CymR and CuO to control gene expres-
sion in mammalian cells using three different strategies
(Fig. 1).
1) Repressor configuration: CymR was used to repress
transcription from a mammalian promoter by binding an
operator site (CuO) placed downstream of the initiationBMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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site. Addition of the inducer (cumate) to mammalian cells
causes a change in the configuration of CymR such that it
can no longer bind DNA and thus relieves repression (Fig
1B).
2) Activator configuration: CymR was fused to an activa-
tion domain and the chimaeric molecule (cTA) was used
to activate transcription from a minimal promoter down-
stream of multimerized operator binding sites (6X-CuO).
Again binding of cTA, and therefore activation, is regu-
lated by addition of cumate (Fig. 1C).
3) Reverse activator configuration: rCymR was fused to
VP16 to give rise to the chimaeric molecule (rcTA) which
was used to activate transcription from a minimal pro-
moter downstream of multimerized operator binding
sites (6X-CuO). Binding of rcTA, and therefore activation,
is induced by addition of cumate (Fig. 1D).
In this report we describe the generation and testing of the
three different configurations of the switch in transient
and stable transfectants.
Results
The repressor configuration
Transient transfections
To assess the potential of the regulatory elements of the p-
cymene operon for regulation of gene expression in mam-
malian cells, we first examined the ability of CymR to
down-regulate the expression of a strong viral promoter
(CMV5: CMV-promoter-enhancer sequences modified by
the addition the Adenoviral tripartite leader sequence and
downstream enhancer elements in the intron 3' to the
transcription initiation site) in mammalian cells (Fig. 1B).
The CymR coding sequence was therefore cloned in an
expression vector (pAdCMV5-K7-GFP) downstream of the
CMV5 promoter to generate pAdCMV5-CymR. 293 cells
were co-transfected with pAdCMV5-CymR, and with,
either pAdCMV5-CuOs-LacZ wherein, expression from
CMV5 can be blocked by the binding of CymR to CuO
inserted at the AscI site at the start site of transcription
(CuOs) or pAdCMV5-CuOg-LacZ, wherein CuO is
inserted 10 bases downstream of the TATA box (CuOg).
Fig. 2A shows that when the reporter construct is trans-
fected alone, high-level expression is detected (lane 2). It
is important to note that these levels are comparable to
those from a parental construct, pAdCMV5-LacZ, lacking
the operator site (lane 1). On co-transfection with the
plasmid pAdCMV5-CymR, 95% of the activity is blocked
by CymR expression (lane 3). In addition, repression is
totally relieved upon the addition of cumate (lane 4).
Similar results are seen when the operator site is intro-
duced in the Age I site in the reporter construct
(pAdCMV5-CuOg-LacZ) (lanes 5–7). In all subsequent
DNA constructs, the configuration corresponding to
Schematic representation of the Cumate switch Figure 1
Schematic representation of the Cumate switch. A. 
Sequences encompassing the promoter regions of p-
cym and p-cmt: P1 and P2 are sequences from the pro-
moter region of two bacterial operons regulated by CymR. 
The arrows represent putative binding sites for a helix-turn-
helix CymR repressor. B. Repressor configuration: The 
bacterial repressor, CymR, can bind to the operator 
sequence (CuO) placed downstream of CMV5, a strong viral 
promoter that is active in mammalian cells. Once bound, 
CymR blocks transcription from the CMV5 promoter. CymR 
bound to cumate is unable to bind to CuO. Transcription 
from CMV5 can proceed unhindered. C. Activator config-
uration: A chimaeric transactivator, cTA can activate tran-
scription from a minimal CMV promoter by binding to six 
repeats of the putative DNA recognition sequence (6X-
CuO) placed upstream of the promoter in the absence of 
cumate. Upon cumate addition, the activator no longer binds 
DNA and therefore is no longer able to activate transcrip-
tion from the basal promoter. D. Reverse activator con-
figuration: A chimaeric transactivator, rcTA can activate 
transcription from a minimal CMV promoter by binding to 
six repeats of the putative DNA recognition sequence (6X-
CuO) placed upstream of the promoter in the presence of 
cumate.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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The Repressor configuration Figure 2
The Repressor configuration. A. Transient transfection: Five micrograms of reporter (pAdCMV5-CuOs-LacZ or 
pAdCMV5-CuOg-LacZ) were transfected alone (lanes 2 and 5 respectively) or co-transfected with 250 ng repressor construct 
(pAdCMV5-CymR) (lanes 3, 4 and 6, 7) in 293 cells. Three micrograms of pcDNA-SEAP was included as an internal control of 
transfection efficiency. Transfections were carried out in the presence (4, 7) and absence (lanes 1, 2, 3, 5 and 6) of 200 µg/ml 
cumate. β-galactosidase (β-gal) activity was measured 48 h post-transfection using a colorimetric assay. Reporter activity was 
normalized to SEAP activity in the culture medium. pAdCMV5-LacZ was used as a reference for promoter strength (lane l). 
The figure represents data from 3 independent experiments. B. Screening 293-CymR clones: Clones of 293 stably express-
ing CymR were infected with AdCMV5-CuOs-LacZ (MOI 10) in the presence and absence of 200 µg/ml cumate. β-galactosi-
dase activity was measured 48 h post-infection using a colorimetric assay in cell extracts. Clone 21, marked with an arrow was 
retained for further experimentation. C. Stable expression of reporter: 293-CymR-CMV5-CuO-GFP cells were cultured 
in the presence and absence of 200 µg/ml of cumate for 48 h. The figure shows flurescent and phase contrast images.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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pAdCMV5-CuOs-LacZ was used and the position is no
longer specified with a suffix.
Stable expression in 293 cells
Having observed tight control in transient transfections,
we determined whether expression could be similarly reg-
ulated in cell lines stably expressing CymR. Therefore the
CymR coding sequence was cloned into an expression
plasmid, pMPG-tk-neo, containing an expression cassette
for the neomycin resistance gene. 293 cells were trans-
fected with pMPG-CymR/tk-neo and a pool of G418-
resistant cells were isolated. To screen for clones that
expressed levels of CymR optimal for tight regulation,
they were infected with AdCMV5-CuOs-LacZ reporter AdV
(an AdV expressing β-galactosidase under the control of
the CMV5-CuO promoter) and LacZ expression was meas-
ured in the absence and presence of cumate (Fig 2B). The
degree of repression varied between 1.7 and 19.4 fold. In
general, clones that showed a high degree of repression
were more difficult to activate and vice versa. 293CymR-
clone 21 was identified as one that exhibits a combination
of efficient repression (ON/OFF ratio 19) and activation.
It was thus chosen for the next step, which was to express
the reporter construct stably.
A reporter plasmid, pAdCMV5-CuO-GFP, containing a
GFP expression cassette wherein GFP expression is regu-
lated by the CMV5-CuO promoter, was stably expressed
in 293CymR clone 21 to generate 293CymR-CMV5-CuO-
GFP clones. Figure 2C shows the performance of the
switch in such a configuration using one of the clones gen-
erated. In the ON state, most cells displayed strong GFP
fluorescence, whereas in the OFF state, only two cells were
visible with fluorescence microscopy although the phase
contrast image shows a dense cellular monolayer. The flu-
orescence index (percentage of GFP positive X mean fluo-
rescent signal) was measured in the ON (9255) and OFF
(37.5) states by flow cytometry. The ON/OFF ratio for this
clone was 246.
The activator configuration
Transient transfections
To transform CymR into a transactivator, it was fused to
the VP16 activation domain such that this chimaeric mol-
ecule could activate transcription by binding multimer-
ized CuO elements (6X-CuO) upstream of a minimal
promoter (Fig. 1C). To this end, the sequences coding for
this chimaeric molecule (cTA) were cloned into an expres-
sion vector, pAdCMV5-K7-BFP giving rise to pAdCMV5-
cTA, where expression of cTA is controlled by the CMV5
promoter. To test the system, pAdCMV5-cTA was co-trans-
fected with a reporter, pAdCR5-LacZ wherein six repeats
of the operator sequence are placed upstream of the CMV
minimal promoter. Reporter and activator constructs were
co-transfected into either 293, HeLa, A549 or BMAdE1 (a
derivative of A549 stably expressing the adenovirus E1
region) cells. Fig. 3A shows that the reporter construct,
pAdCR5-LacZ, when transfected alone, produced mini-
mal amounts of β-gal activity. On co-transfection with the
plasmid coding for the transactivator, there was a large
increase in the β-gal activity. Addition of cumate to the
medium reduced the activation to different extents in the
various cell lines, resulting in ON/OFF ratios of 8.6 +/-
2.1, 13 +/- 7.8, 10.3 +/- 6.0 and 7.7 +/- 0.95 in 293, A549,
BMAdE1-78, and HeLa cells respectively. Both operator
sequences (P1 and P 2; Fig. 1A) perform equally well to
mediate transactivation (data not shown), therefore all
subsequent experiments were performed with the mul-
timerized P2 elements linked to the CMV TATA box (CR5
promoter).
Stable expression in 293 cells
The cTA hybrid gene was cloned into an expression plas-
mid, pcDNA, containing an expression cassette for the
neomycin resistance gene. 293 cells were transfected with
pcDNA-cTA and a pool of G418-resistant cells were iso-
lated. Less than 10 clones were obtained, which were
screened by infection with AdCR5-LacZ reporter AdV (an
AdV expressing β-galactosidase under the control of the
CR5 promoter). Clone 30 was chosen for the highest level
of activity and the best ON/OFF value, and further sub-
cloned by limiting dilution. Reporter gene activity in 5 of
the sub-clones were close, varying between 4.9 and 7.8.
Activator configuration Figure 3
Activator configuration: Transient transfection: 
Reporter construct (pAdCR5-LacZ) was transfected alone 
(P1) or was co-transfected with activator construct, 
pAdCMV5-cTA (Cu- and Cu+), in 293, A549, BMAdE1-78 
and HeLa cells. pcDNA-SEAP was included to serve as a con-
trol for transfection efficiency. Transfections were carried 
out in the presence (Cu+) and absence (Cu-) of 200 µg/ml 
cumate. β-galactosidase activity was measured 48 h post-
transfection. Reporter activity was normalized to SEAP activ-
ity in the culture medium. The figure represents data from 3 
independent experiments.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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Clone 30–37 has the best ON/OFF ratio (7.8) and was
thus chosen for further experimentation. It is noteworthy
that, following adenoviral infection in 293 cells, the
expression cassette is amplified to greater than 10E5 cop-
ies per cell and, as a result, the basal level of expression
from the minimal promoter is fairly high as reported ear-
lier [29]. Therefore the efficacy of the cTA to affect tight
regulation from the CR5 promoter was further examined
under low copy number as is the case in stable expression
systems. Thus the selected 293cTA clone (clone 30–37)
was transduced with reporter lentivirus, Lenti-CR5-GFP,
wherein GFP expression is regulated by the CR5 promoter,
giving rise to 293cTA-CR5-GFP pool. Reporter gene
expression of the 293cTA-CR5-GFP was studied in com-
parison to 293CymR-CMV5CuO-GFP for dose response
to cumate as follows.
Dose response of the repressor and activator 
configurations
To determine whether the control of gene expression was
dose-dependent, cell lines stably expressing the repressor
(293CymR-CMV5-CuO-GFP) or activator (293cTA-CR5-
GFP) configurations of the switch were cultured under
conditions where gene expression is OFF (293CymR-
CMV5-CuO-GFP in the absence of cumate and 293cTA-
CR5-GFP in the presence of cumate). It is important to
keep gene expression OFF while isolating a cell line stably
expressing a gene of interest, because the expression of
certain proteins may interfere with cell growth and thus
with the process of isolating stable clones. To initiate the
experiment, cells were washed and incubated in different
concentrations of cumate. GFP expression was measured
by flow cytometry, 48 h later. In the case of 293CymR-
CMV5-CuO-GFP GFP fluorescence was almost at back-
ground levels (% GFP+ cells = 1.45 and mean fluorescence
intensity (MFI) = 6, Fluorescence index = 8.7) without the
addition of cumate (Fig. 4). Upon the addition of 3 µg/ml
of cumate 93% of the cells are GFP +, with a MFI of 9.5,
giving a fluorescence index of 883. Further addition of
cumate increases the MFI to 25.2 and 29.3 at 5 µg/ml and
10 µg/ml cumate respectively. At 10 µg/ml, the switch is
maximally activated, since further addition of cumate (up
to 100 µg/ml) does not result in any significant increases
in MFI (30). The maximal ON/OFF ratio is thus 330.
In the 293cTA-CR5-GFP cell pool generated by lentiviral
transduction of the reporter, the switch is maximally ON,
65 % cells being GFP+ with an MFI of 49, without the
addition of cumate (Fig. 4(i) and (iii)). Upon the addition
of 0.5, 1.0, 3.0, 5.0, 10.0 30.0, 50.0 and 100.0 µg/ml of
cumate 46%, 38%, 19%, 9%, 6%, 5%, 3% and 2% of the
cells are GFP +, with MFIs of 25, 19, 10, 7, 6, 5, 6 and 6
respectively. At 30 µg/ml, the switch is completely OFF,
since additional increases in the cumate concentration
does not cause a significant reduction in, either the per-
centage of GFP+ cells or the MFI. The maximal ON/OFF
ratio is thus 237.
Reverse activator configuration
To further increase the versatility of the cumate switch, we
undertook a screen of CymR mutants to isolate a variant
that would bind DNA in the presence rather than the
absence of cumate. We chose to perform the screen in
mammalian cells using an adenoviral vector for delivery
of the mutant library [30,31].
Screening an adenoviral library of CymR mutants
Generating host cell line: 293CR5-LacZ
In order to efficiently screen the library of the mutated
transactivator, cTA, a stable 293 cell line with optimized
sensitivity for cumate induction was established by stable
expression of a β-galactosidase reporter, pAdCR5-LacZ-
neo in 293 cells. Fig. 5A shows the reporter activity of 7 of
the resulting G418-resistant clones when infected with an
AdV expressing the transactivator (AdCMV5-cTA) in the
presence and absence of cumate. Of the more than 100
clones screened, Clone 13 was retained for further analy-
sis since it displayed both a strong level of induction and
the best ON/OFF ratio (40X). As shown in Fig. 5B, when
AdCMVcTA was plated on 293CR5-LacZ at 100–300
plaques per plate, the plates are clearly white in the pres-
ence of cumate and blue in the absence of cumate as a
result of β-galactosidase expression.
Screening the adenoviral library
Error prone PCR was used to generate a library of mutated
CymR molecules. Three PCR products with varying levels
of nucleotide mis-incorporation, ranging from 0–3 to 7–
16 mutations/kb were obtained and subcloned into plas-
mid pAdPSCMV-cTA-DC-GFP, where they replaced the
wild-type CymR. Thus three different libraries with vary-
ing frequencies of mutations, each with approximately 2.5
× 105 recombinant E. coli clones, were established. The
plasmid pools were used as transfer vectors to generate
adenoviral libraries using the positive selection system
[30].
The library was plated on 293-CR5-LacZ cells in the pres-
ence and absence of cumate, to screen for plaques that
were β-galactosidase positive in the presence of cumate as
opposed to the wild-type cTA where plaques are β-galac-
tosidase positive in the absence of cumate. Approximately
60,000 plaques were screened. However, only 15 gave the
desired phenotype and were therefore picked for analysis.
Of these, the majority were not regulated by cumate. Only
one mutant satisfied the criteria for being a reverse
mutant.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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A. Dose-dependent control of reporter gene expression by cumate Figure 4
A. Dose-dependent control of reporter gene expression by cumate: 293CymR-CMV5-CuO-GFP and 293cTA-CR5-
GFP cells that were cultured under conditions where reporter gene expression was off (293CymR-CMV5-CuO-GFP in the 
absence of cumate and 293cTA-CR5-GFP, in the presence of 50 µg/ml cumate) were washed with PBS and incubated for 48 h 
in the presence of varying concentrations of cumate. Total GFP fluorescence was measured by flow cytometry and is indicated 
in the y-axis in terms of fluorescence index (% GFP positive cells X mean fluorescence index). The figure represents the data 
from triplicate measurements. B. Tight control of GFP expression in cells stably expressing CymR and pCMV5-
CuO-GFP: A clone of 293CymR-CMV5-CuO-GFP was cultured for 48 h in the presence of various concentrations of cumate. 
The figure shows representative fluorescent images of the cells treated with 0, 3 and 30 µg/ml of cumate from the experiment 
shown in the panel A. C. Tight control of GFP expression in cells stably expressing cTA and pCR5-GFP: The 
enriched pool of 293cTA-CR5-GFP, that was cultured in the presence of cumate, was washed in PBS and incubated for 48 h in 
the presence of various concentrations of cumate. The figure shows representative fluorescent images of the cells treated with 
0, 0.5 and 10 µg/ml of cumate from the experiment shown in the panel A.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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A. Screening of 293-CR5-LacZ clones Figure 5
A. Screening of 293-CR5-LacZ clones. G418-resistant clones were infected with AdCMV-cTA in the presence and 
absence of 200 µg/ml cumate. Forty-eight hours later, β-Gal activity was measured. The figure shows the subclone # 13 dis-
plays high-level expression and the best ON/OFF ratio, almost 40-fold. B. Screening adenoviral library of cTA mutants. 
293CR5-LacZ cells were infected with the adenoviral library of CymR mutants and overlayed with agarose supplemented with 
Blue-gal. Plaques formed by the infection of adenovirus expressing the wild-type cTA are β-gal positive in the absence of 
cumate, and β-gal negative in the presence of 200 µg/ml cumate. C. The plaque indicated by an arrow is a candidate for the 
reverse phenotype, since high β-gal expression is evident in the presence of 200 µg/ml cumate.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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The reverse activator in transient transfections
The mutated CymR sequence was amplified from the viral
DNA and cloned into pAdCMV5cTA replacing the wild
type CymR to give rise to pAdCMV5rcTA. Sequence com-
parison of the wild-type and mutated DNA revealed three
mutations (Ala125→Val125, Glu142→Gly142  and
Met144→Ile144) in the 3'-half of the cDNA.
Transient transfections were performed to further charac-
terize the reverse phenotype of the mutated CymR Fig. 6).
As seen in Fig. 6A, whereas β-galactosidase activity is
induced in the absence of cumate in the case of the cTA, it
is induced in the presence of cumate, in the case of the
rcTA. Quantitation of the transfection results are shown in
Fig. 6B. The rcTA activates transcription in the presence of
cumate, with an ON/OFF ratio of 6. The cTA, on the other
hand, regulates transcription more efficiently, with an
ON/OFF ratio of 14, despite the fact that it can activate to
higher levels (Fig. 6B).
Regulation of expression of the reverse activator
Although the mutant has the desired phenotype, we
wanted to explore the possibility of improving its ability
to regulate gene expression. We thus regulated the expres-
sion of the rcTA using a strategy that is illustrated in Fig.
7A. We hypothesized that in the absence of cumate, CymR
would block the expression of rcTA from the plasmid
pAdCMV5-CuO-rcTA, maintaining reporter gene expres-
sion from the rcTA-dependent pAdCR5-LacZ, at minimal
levels. In the presence of cumate, however, both the
expression and the activation function of the rcTA should
be induced and reporter gene expression will be at maxi-
mal levels. To experimentally verify the advantage of this
strategy, two cell lines stably expressing rcTA were gener-
ated. A lentiviral vector expressing the rcTA under the con-
trol of the CMV5-CuO promoter was used to transduce
the parental 293 cells and a clone of 293 (293CymR) that
stably expresses CymR, thus regulating expression from
the CMV5 promoter (described above in section on the
repressor configuration). The two cell pools (293-rcTA
and 293CymR-rcTA) were sub-cloned by limiting dilu-
tion. The level of reporter gene expression upon lentiviral
infection of representative 293rcTA and 293CymR-rcTA
clones with lentiCR5-GFP is shown in Fig. 7B and 7C
respectively. The superior level of regulation in the
293CymR-rcTA sub-clones is evident. To better assess the
induction factor, SEAP was subsequently used as a
reporter since it allows for more precise measurements
than GFP in cases of low-level expression, such as un-
induced conditions. 293-CymR-rcTA#40 and 293rcTA#18
were retained for transduction with a lentiviral reporter
(lenti-CR5-SEAP-IRES-GFP). For the sake of comparison,
293 cells stably expressing the cTA (293cTA described in
section on the activator configuraion) were also trans-
Comparison of cTA and rcTA activity and expression Figure 6
Comparison of cTA and rcTA activity and expression: A. 293-CR5-LacZ cells were transfected with pAdCMV5-cTA 
or pAdCMV5-rcTA in the absence or presence of 200 µg/ml cumate. Forty-eight hours later the cells were stained for β-gal 
activity. B. 293-CR5-LacZ cells were co-transfected with pcDNA-SEAP and pAdCMV5cTA or pAdCMV5-rcTA in the pres-
ence or absence of 200 µg/ml cumate. β-galactosidase activity was measured 48 h post-transfection. Reporter activity was nor-
malized to SEAP activity in the culture medium. The figure represents data from 3 independent experiments.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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duced with the same reporter lentivirus. By monitoring
GFP expression, the three pools were deemed to contain a
similar percentage of transduced cells (76, 52 and 72 for
293cTA-CR5-GFP, 293rcTA-CR5-GFP and 293CymR-
rcTA-CR5-GFP respectively). The results for the three cell
pools are shown in Fig. 7D, which demonstrated a signif-
icant increase in the ON/OFF ratio by regulating the
expression of the rcTA. The data also shows that the dou-
ble regulation result in superior induction factor (700-
fold) as compared to the 293-rcTA due to significant
reduction in basal level under un-induced condition.
Discussion
We have described the construction of a new inducible
system for expression in mammalian cells. We have
adapted the regulatory mechanism of a bacterial operon
derived from Pseudomonas putida to a mammalian expres-
sion system using three different strategies (Fig. 1). Since
Regulating rcTA expression Figure 7
Regulating rcTA expression. A. Schematic representation of the strategy. The expression of rcTA is controlled by 
the CMV5-CuO promoter. In the absence of cumate, CymR binding to CuO blocks the synthesis of rcTA. In the absence of 
rcTA, GFP expression from CR5-GFP is not stimulated. Leaky expression of rcTA is not sufficient to activate transcription 
from the CR5 promoter. Upon addition of 50 µg/ml cumate, CymR binding to CuO is abrogated and therefore rcTA is synthe-
sized. Cumate binding to rcTA activates its DNA binding activity thereby turning on reporter gene expression. B. Screening 
of 293-rcTA and C. 293CymR-rcTA clones. The clones were infected with lenti-CR5-GFP in the presence and absence of 
50 µg/ml cumate and 48 h later GFP fluorescence was measured by flow cytometry. D. Stable expression of reporter 
CR5-SEAP-IRES-GFP in 293-rcTA and 293CymR-rcTA: 293cTA, 293-rcTA and 293CymR-rcTA transduced with lenti-
CR5-SEAP-IRES-GFP were cultured in the presence and absence of 50 µg/ml cumate for 48 h. SEAP activity was measured in 
the cell culture medium.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
Page 11 of 18
(page number not for citation purposes)
cumate is the effector molecule that regulates the CymR-
mediated expression and therefore CymR-DNA binding,
it is the molecule we have used to regulate expression
from the mammalian expression system incorporating
CymR. It is important to note that, at concentrations that
effectively control gene expression, mammalian cell
growth is not affected over 10 passages (data not shown).
The different strategies we have chosen to build an induc-
ible system for expression in mammalian cells have been
used before and have proven to be highly successful
[9,19,32]. This approach is particularly attractive because
it lends itself very well to improvement as a consequence
of its modular nature. A very well studied example of a
chimaeric transactivator is the tTA where the Tet repressor
has been transformed into an activator by fusion with the
VP16 activation domain [13]. The repressor is fused to an
activation domain, the two modules being functionally
independent. It is possible thus to improve and exchange
the activation domain without affecting repressor func-
tion. Modifications in the VP16 transactivation domain
have been identified that render it less toxic, while main-
taining its activation potential [18]. It is similarly possible
to modify the DNA-binding or dimerization properties of
the repressor and leave the transactivation function
unchanged [33,34]. A large number of such improve-
ments have been described for the Tet system in the liter-
ature (reviewed in ([9,19,35]). More recently, macrolide-
and streptogramin-based gene-switches were also modi-
fied so as to render them more versatile [26].
In the first strategy CymR is used as a repressor that revers-
ibly blocks expression from a strong promoter. The oper-
ator sequence was inserted at two different sites with
respect to the TATA box since there is some debate in the
literature as to the role of site of insertion. A detailed study
by Hu and Davidson wherein lac operator sequences are
inserted at different positions in the SV40 promoter
region, indicates that in all cases there is a decrease in pro-
moter activity due to the insertion per se [36]. More
recently, Hedengren-Olcott and Hruby [37] have demon-
strated that the activity of the vaccinia virus GIL promoter
is reduced by the insertion of the tetO sequence. In our
case, insertion in two different positions (between the
TATA box and the initiation site or just downstream of the
initiation site) did not affect expression (Fig. 2A). Simi-
larly, Yao et al. [14] did not see any decrease in promoter
activity as a result of the insertion of the Tet operator site.
They reported efficient repression and attributed the suc-
cess of their strategy to the positioning of the operator site.
The positioning was such that the operator was 10 base
pairs downstream of the TATA box, resulting in repressor
binding on the same side of the helix as the RNA polymer-
ase. The repressor is therefore able to sterically block the
polymerase most effectively. In our case it is not possible
to make a definitive prediction regarding DNA-CymR
interaction, since the exact sequence requirements for
CymR binding to DNA are not yet known. Work is in
progress to define sequences, both in the repressor and in
the DNA, that participate in this interaction.
Tight control of transgene expression in a cell line stably
expressing CymR is evident by examining GFP expression
in 293-CMV5-CuO-GFP cells. Fig. 4B allows a visual
appreciation of the tight control in the OFF state. Such
tight regulation of gene expression is comparable to that
reported for established cell lines being used in inducible
expression systems [14,38,39]. Although this strategy
offers great promise for stable expression of a heterolo-
gous protein, it is limited by the strength of the CMV5 pro-
moter in the relevant cell line.
To generate a regulatory system that would be more versa-
tile in its application, we also generated a configuration of
the switch that would be relatively independent of cellular
transcription factors. The chimaeric transactivator, cTA,
which is active in several cell lines tested (293, A549,
BMAdE1 and HeLa (Fig. 3A) and Peer, CHO (data not
shown) can activate transcription from multimers of
either the perfect or imperfect repeat. The perfect palin-
drome, may be expected to be a better binding site for
CymR. However, in our assay no significant difference was
observed between the two sequences (data not shown).
Perhaps, the differences in the two halves of the imperfect
repeat are not in critical bases. Moreover, in both cases six
copies of the putative recognition sequence are used.
Cooperative binding of several activator molecules to the
multimerized site may overcome any minor difference in
binding activity to individual sites.
Depending upon the application in question, it may be
necessary to partially turn the expression of a gene of
interest, on or off. We therefore investigated the dose
response of reporter gene expression in both repressor and
activator configurations of the switch. We chose to use
flow cytometry since it has the advantage of providing
information both on the fraction of cells expressing trans-
gene and the intensity of transgene expression, as opposed
to techniques where global expression is measured in a
cellular extract (for example, luciferase). Our data reveal
changes at both levels, fraction of cells expressing trans-
gene and the intensity of transgene expression upon the
addition of cumate and show that, indeed reporter gene
expression is regulated in a dose-dependent manner.
As expected, in the activator configuration, transgene
expression is ON in the absence of cumate, which for cer-
tain applications would require culturing cells in the pres-
ence of cumate to keep transgene expression off until
appropriate. Moreover, cumate would have to be removedBMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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from the culture medium to turn expression ON. This can
be problematic for different reasons including the delay in
turning on expression related to the incomplete removal
of cumate and the inconvenience of removing cumate
from very large culture. We thus carried out a screen of
mutant transactivators to identify a reverse mutant. A sim-
ilar screen was carried out to identify the reverse Tet acti-
vator, rtTA. A first screen in a bacterial system identified
the first generation of rtTA [33]. However, a reverse
mutant with better regulatory properties was isolated in a
later screen in a eukaryotic cell type, Saccharomyces cere-
visae  [40]. To increase the probability of identifying a
mutant with optimal function in mammalian cells, we
undertook the screen in 293 cells. However, this is a task
with several technical challenges, a major one being the
isolation of a host cell that has taken up the desired
mutant and presuming this is successful, then, the isola-
tion of the mutated DNA from the cell. We thus used ade-
noviral vectors to deliver the library, since plaque-
formation results in the localized amplification of indi-
vidual AdV and isolation of the mutated DNA from the
adenoviral genome is straightforward. Our proprietary
technology for the positive selection of recombinant ade-
noviruses further facilitated the task [30]. Of all the
mutants screened, only one had the desired reverse phe-
notype with respect to regulation of CuO binding by
cumate. The rcTA thus isolated, although functional, is
sub-optimal in its regulatory function. All three mutations
are in the 3'-half of the cDNA. Work is in progress to gain
an insight into the structure-function analysis of the
CymR to rationally design mutants with optimized
cumate-regulated DNA binding properties. In the mean
time we decided to take advantage of the opposite regula-
tion by cumate of DNA binding of CymR and rcTA similar
to what was done for the Tet system by Freundlieb et
al.[16]. We thus controlled the expression of the rcTA
using CymR and generated cell lines with optimal regula-
tion of gene expression in the reverse configuration and
were thus able to obtain tight control of gene expression
which is relatively cell-type independent and can be
turned ON with the addition of the inducer molecule,
cumate.
Conclusion
In summary, we have demonstrated the feasibility of har-
nessing the regulatory elements of the p-cym operon from
Pseudomonas putida to regulate gene expression in mam-
malian cells. In both the repressor and activator configu-
rations, we have demonstrated tight control of gene
expression both in transient and stable expression.
Although both systems have advantages, as might be
expected, they also have limitations for various applica-
tions. To use the repressor configuration, it is imperative
that a suitable promoter be available for the cell line in
question. Although this is rectified with the use of the cTA,
gene expression cannot be turned ON by the addition of
an inducer in this case. There is thus a need for the
removal of cumate, which could be inconvenient in situa-
tions such as large-scale protein production. To increase
the versatility of the expression system, we have isolated a
reverse mutant, which allows gene expression to be turned
on in the presence rather than absence of cumate.
Although the reverse mutant is sub-optimal, we have
combined two configurations of the switch to generate
tight control of gene expression. We thus have a versatile
system with various configurations.
Methods
Plasmids
All plasmids named with pAd are adenoviral transfer vec-
tors containing viral sequences between 0 – 1.4 and 9.4 –
15.5 map units that are required for homologous recom-
bination to generate Ad recombinants. Their presence
should not result in the synthesis of viral proteins. The
plasmids used in this study are listed in Table 1.
Table 1: List of plasmids used in this study.
Plasmid name Configuration Promoter Coding 
sequence
Purpose
pAdCMV5-CuOg-LacZ Repressor CMV5-CuO LacZ Reporter for transient transfection
pAdCMV5-CuOs-LacZ Repressor CMV5-CuO LacZ Reporter for transient transfection and adenovirus for 
screening stable transfectants of CymR
pAdCMV5-CuO-GFP Repressor CMV5-CuO GFP Reporter for stable expression of repressor configuration
pAdCMV5-CymR-K7-BFP Repressor CMV5 CymR Repressor expression in transient transfection assays
pMPG-BFP/CMV5- CymR/tk-neo Repressor CMV5 CymR Stable expression of CymR
pAdCR5-LacZ Activator CR5 LacZ Reporter gene for transient transfection.
pAdCMV5-cTA- K7BFP Activator CMV5 cTA Expression of activator for transient transfection
pcDNA-cTA Activator CMV cTA Stable expression of activator
pAdPS-CMV-cTA-DC- GFP Activator CMV cTA Transfer vector for generating adenoviral library for mutant 
cTAs
pAdCMV5-rcTA- K7BFP Reverse activator CMV5 rcTA Expression of reverse activator for transient transfection
pRRL.cppt.CMV5- CuO-rcTA.WPRE Reverse activator CMV5-CuO rcTA Vector for generating lentivirus expressing the rcTA
pRRL.cppt.CR5- GFP.WPRE Activator/Reverse activator CR5 GFP Reporter for lentiviral transduction
pRRL.cppt.CR5-SEAP-IRES-GFP.WPRE Activator/Reverse activator CR5 SEAP and GFP Reporter for lentiviral transduction
pAdCR5-GFP Activator/repressor CR5 GFP Transfer vector for generating adenovirus for screening cell 
lines stably expressing cTA.BMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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Repressor configuration
pAdCMV5-CuOg-LacZ
A single operator site (CuO) has been introduced at the
start site of CMV5, a strong constitutive promoter, driving
the expression of the β-galactosidase reporter gene. The
following steps were used to achieve this: A unique AgeI
site was introduced in the promoter region of the CMV
minimal promoter in pAdCR5-LacZ (described below)
such that the site was 10 bp downstream of the TATA box
using a PCR-based approach. Then, a 469 bp fragment
corresponding to the promoter-enhancer region of CMV5
(-53 to -522) was amplified by PCR using pAdCMV5-K7-
BFP [41] as the template. pAdCR5-LacZ-AgeI was digested
with HindIII to remove the operator elements (6X-CuO)
and the CMV5 PCR fragment was cloned as a HindIII frag-
ment to generate pAdCMV5LacZ-AgeI. Complementary
oligonucleotides were designed such that the ends of the
annealed molecule were compatible with sticky end liga-
tion in an AgeI-digested vector. The oligonucleotide con-
tained one copy of the cumate operator sequence from P2
(P2-CuO: AACAAACAGACAATCTGGTC TGTTTGTA; Fig.
1A). The double stranded molecule was cloned into AgeI
site of pAdCMV5-Og-LacZ. The AgeI site is 9 bp down-
stream of the TATA box.
pAdCMV5-CuOs-LacZ
pAdCR5-LacZ was digested with HindIII to remove the
6X-CuO and the 469 bp CMV5 promoter-enhancer PCR
fragment (described above) was cloned into the HindIII
site to give rise to pAdCMV5-LacZ. Complementary oligo-
nucleotides were designed such that the ends of the
annealed molecule were compatible with sticky end liga-
tion in an AscI-digested vector. The oligonucleotide con-
tained one copy of the cumate operator sequence from P2
(P2-CuO). The AscI site is at the start site of transcription.
pAdCMV5-CuO-GFP
pAdCMV5-GFP [29] was partially digested with BamHI
and completely with XhoI. A 1084 bp fragment including
the GFP coding sequence and a part of the 5' UTR
sequences was cloned into pAdCMV5-CuOs-LacZ that
was digested with XhoI (partially) and BamHI to remove
the LacZ coding sequences. Thus pAdCMV5-CuO-GFP
and pAdCMV5-CuOs-LacZ both contain the same pro-
moter elements, but differ in the reporter gene (GFP and
LacZ respectively) downstream of the promoter.
pAdCMV5-CymR-K7-BFP
pAdCMV5-CymR-K7-BFP is a plasmid with two expres-
sion cassettes, one expressing the repressor (CymR) under
the control of the CMV5 promoter and the other, express-
ing BFP driven by the CMV promoter). The VP16 activa-
tion domain was excised from pAdCMV5-cTA-K7-BFP
(described below), which is a similar vector expressing the
chimaeric transactivator, CymR-VP16 or cTA. An intra-
molecular ligation was carried out to generate pAdCMV5-
CymR-K7-BFP. This plasmid will be referred to as
pAdCMV5-CymR in the manuscript for the sake of brev-
ity.
pMPG-BFP/CMV5-CymR/tk-neo
This expression plasmid for CymR (pMPG-CymR/tk-neo)
was used to generate cell lines stably expressing the repres-
sor. It comprises of three independent expression cas-
settes, a) one for the expression of CymR, using the CMV5
promoter, b) a second cassette where the CMV promoter
drives BFP expression. BFP was used as a reporter gene to
facilitate identification of transfected cells, and a third cas-
sette for the expression of the G418 (neo)-resistance pro-
tein. It was derived from the pMPG series of vectors
described in Gervais et al.[42]. pKCMVB43 [43] was
digested with HindIII, rendered blunt and dephosphor-
ylated and used to sub-clone the CymR coding sequence
as a blunt-ended PCR fragment. The resulting plasmid was
called pKCMV5-CymR. The CymR expression cassette
(including the CMV5 promoter, the CymR coding
sequence and the polyadenylation sequence) was excised
as an AscI fragment from pKCMV5-CymR. This was then
cloned into the AscI site of pMPG-BFP-tk-neo to give rise
to pMPG-BFP/CMV5-CymR/tk-neo, referred to as pMPG-
CymR/tk-neo in the manuscript for the sake of brevity.
Activator configuration
pAdCR5-LacZ
pAdCR5-LacZ was generated by removing the Tet operator
sequences from pAdTR5-LacZ [41] and replacing them
with the Cumate operator sequences. Therefore, pAdTR5-
LacZ was digested with XhoI to remove the Tet operator
sequences, the minimal promoter element and most of
the Ad-tpl. The minimal promoter element and the Ad tpl
were re-cloned into an XhoI-digested pAdTR5LacZ as a
PCR fragment. The primers were designed such that the
resulting fragment was flanked by XhoI sites and a new
HindIII site was inserted. This intermediate vector was
called pAdHindIIILacZ. A double stranded oligonucle-
otide (6X-CuO) containing six repetitions of the operator
sequence from P1 (P1-CUO: AAAGAAACAAACCAACCT-
GTCTGT ATTATC) was then cloned into the HindIII site of
pAdHindIIILacZ to give rise to pAd CR5-LacZ.
pAdCMV5-cTA-K7-BFP
pAdCMV5-cTA-K7-BFP is a plasmid with two expression
cassettes, one expressing the activator (cTA) under the
control of the CMV5 promoter and the other, expressing
BFP driven by the CMV promoter). To generate the chi-
maeric transactivator, oligonucleotides were designed to
perform a PCR reaction on the CymR coding sequence
such that the initiator methionine was in the context of a
Kozak sequence. Similarly oligonucleotides were
designed to perform a PCR reaction on amino acid 363 toBMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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490 of the herpes simplex virus protein 16 (VP16). The
two PCR fragments were cloned into pAdCMV5-K7-BFP
[41] in a three-way ligation to create an expression vector
wherein the CMV5 promoter was driving the expression
of the chimaeric protein, CymR-VP16 (pAdCMV5-cTA-
K7BFP). This plasmid will be referred to as pAdCMV5-cTA
in the manuscript for the sake of brevity.
pcDNA-cTA
A PCR fragment encompassing the cTA coding sequence
was cloned in the multiple cloning site downstream of the
CMV promoter in pcDNA-SEAP [44].
pAdPS-CMV-cTA-DC-GFP
To construct the transfer vector for generating the adeno-
viral library, pAdPS-CMV5-CuO-cTA-DC-GFP, a parental
vector that expressed the adenoviral protease coding
sequence (PS) under the control of the adenoviral major
late promoter (mlp) [31], was digested with BglII to
remove the CMV5-CuO promoter. Two PCR gragments, a)
CMV promoter enhancer and b) cTA were cloned into the
BglII-digested vector. This plasmid will be referred to as
pAdPSCMV-cTA in this manuscript for the sake of brevity.
pRRL.cppt.CMV5-CuO-rcTA.WPRE
A SpeI-SmaI fragment encompassing part of the CMV5
promoter and the cTA coding sequence in
pRRL.cppt.CMV5-cTA-WPRE (Broussau et al in prepara-
tion) was replaced by a SpeI-SmaI fragment (CMV5-CuO-
rcTA) to give pRRL.cppt.CMV5-CuO-rcTA.WPRE.
pAdCR5-GFP
pAdCR5-GFP was generated from pAdTR5-GFP [41] by
exchanging the Tet-regulated promoter for the cumate-
regulated promoter (AflII-BlpI fragment).
pRRL.cppt.CR5-GFP.WPRE
The lentiviral backbone, pRRL.cppt.CR5-GFP.WPRE was
derived from pRRL.cppt.hPGK-eGFP.WPRE [45] employ-
ing the following steps. A fragment of DNA encompassing
the CMV5 promoter linked to the GFP coding sequences
was amplified by PCR from the plasmid pUC19-CMV5-
GFP. The DNA fragment was digested with ClaI, followed
by treatment with T4 DNA polymerase to render the ClaI
site blunt. This was then followed by a digestion with SalI.
The hPGK promoter and eGFP sequences in
pRRL.cppt.hPGK-eGFP.WPRE were replaced by the CMV5
promoter and GFP coding sequences respectively by exci-
sion of the former by digestion of pRRL.cppt.hPGK-
eGFP.WPRE with EcoRV and SalI and followed by ligation
with the CMV5-GFP fragment. The CMV5 promoter in
pRRL.cppt.CMV5-GFP.WPRE was then replaced by the
CR5 promoter from pAdPS-CR5mcs-IRES-GFP by
exchanging the XhoI fragments of the two plasmids.
pRRL.cppt.CR5-SEAP-IRES-GFP
The AscI-SpeI (the AscI site digests in the CR5 sequence
and SpeI in the GFP coding region) of pRRL.cppt.CR5-
GFP.WPRE was replaced with that from pAdCR5-SEAP-
IRES-GFP.
Cells and transient transfection
293, A549, BMAdE1-78-42 (an A549 clone expressing the
E1 region of Ad5) [46], and HeLa cells were maintained in
DMEM supplemented with 10% heat inactivated FBS and
2 mM glutamine. All reagents for cell culture were pur-
chased from Gibco-Invitrogen, (Burlington, ON, Can-
ada).
Transfection conditions were optimized for each of the
cell lines studies. 293 and HeLa cells were transfected
using the calcium phosphate technique. One ml of DNA-
calcium phosphate precipitate contained a total of 10 µg
DNA (5 µg of reporter (pAdCMV5-CuOs-LacZ or
pAdCMV5-CuOg-LacZ or pAdCR5-LacZ), 0.5 µg of repres-
sor (pAdCMV5-CymR) or activator (pAdCMV5-cTA) and
3 µg of pcDNA-SEAP). This was divided equally between
two 60 mm plates, each containing 106 293 cells. One of
the two plates received in addition 200 µg/ml cumate.
pcDNA-SEAP [44] was included in all transfections, so
that secreted alkaline phosphatase (SEAP) activity could
be used to normalize for transfection efficiency. 293CR5-
LacZ were transfected with 400 ng of activator
(pAdCMV5rcTA or pAdCMV5cTA) plasmid DNA and 2 µg
of carrier DNA mixed with 4.8 µl of PEI in the presence
and absence of 200 µg/ml of cumate. Transfections in
A549 and BMAdE1-78 cells were carried out using Genep-
orter (Gene Therapy Systems Inc. San Diego, CA) accord-
ing to manufacturer's directions. Briefly, 3 µg DNA (2 µg
pAdCR5-LacZ, 25 ng pAdCMV5-cTA and 0.5 µg pcDNA-
SEAP) in 500 µl DMEM was added to 1 × 105 A549 or 6 ×
105 BMAdE1-78 cells in 500 µl DMEM. After 3 h, 1 ml
DMEM was added to the plates so that the final concentra-
tion of serum was 10% and half the plates received
cumate at a concentration of 200 µg/ml.
SEAP and β-galactosidase activity: SEAP activity was meas-
ured as described [44]. Briefly, 50 µl of 2X SEAP buffer (1
M diethanolamine pH 9.8, 2 mM MgCl2, 10 mM 1-
homoarginine and 20 mM p-nitrophenyl phosphate, dis-
odium, hexahydrate Sigma 104 phosphatase substrate;
Sigma-Aldrich, Oakville, Ontario, Canada) was added to
50 µl of cell culture medium. OD405 was read using a plate
reader after incubation at room temperature for different
intervals of time. This information was used to ensure that
the enzyme activity was measured under conditions
where the substrate was in excess. Colorimetric assay for
β-galactosidase (β-gal) activity was measured in trans-
fected/infected cell extracts. Cells were lysed 48 h post-
transfection by three freeze-thaw cycles in 0.25 M Tris.HClBMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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pH 8. The cell lysate was centrifuged at 14,000 × g and
enzyme (β-galactosidase) activity was measured in the
supernatant (cell extract) using a colorimetric assay con-
taining 1 mM MgCl2, 0.9 mg/ml O-nitrophenyl β-D-
Galacto-pyranoside (ONPG), and 66 mM sodium phos-
phate (pH 7.5). Reactions were incubated at 37°C until a
faint yellow color had developed. OD420 was measured at
regular intervals until the reaction appeared to plateau. To
stain transfected cells for β-galactosidase activity, cells
were washed with PBS, fixed with glutaraldehyde (0.5%
glutaraldehyde in PBS for 3 mins. at room temperature),
washed again and incubated in β-galactosidase buffer (50
ml contains 1 ml of a 20 mg/ml X-gal solution in dimeth-
ylformamide, 0.05 gm magnesium chloride (1 mM),
0.082 gm potassium ferricyanide (5 mM) and 0.11 gm
potassium ferrocyanide (5 mM)) for 4–16 h at room tem-
perature in the dark at which point the β-galactosidase
buffer was washed off [47].
Stable cell lines
293-CymR were generated by transfecting 1 × 106 293 cells
with 10 µg of pMPG-CymR/tk-neo by the calcium phos-
phate technique. G418 (400 µg/ml) was added to the
growth medium 48 h after the transfection to select a pool
of G418-resistant cells. Individual clones (293-CymR)
were isolated from this pool by the method of limiting
dilution and tested for CymR function by infection with
AdCMV5-CuO-LacZ.
293CymR-CMV5-CuO-GFP  clones were generated by
transfecting 1 × 106 293-CymR clone 21 with 10 µg of
pAdCMV5-CuO-GFP. GFP expression was induced by the
addition of 200 µg/ml cumate and individual GFP posi-
tive cells were picked by Quixell™ [48]. Total GFP fluores-
cence was measured using an EPICS™XL-flow
cytofluorometer (Beckman Coulter, Fullerton, CA)
equipped with 15 mW at 488 nm argon ion laser as an
excitation source. The green fluorescence emission was
detected using a 550 nm dichroic long pass and a 525 nm
band pass filter set. The fluorescence index was calculated
by multiplying the percentage of positive cells by the
mean fluorescence value.
293-cTA  cells were generated as described above for
293CymR except that pcDNA3-cTA was used for the trans-
fection. G418-resistant clones were tested by infection
with AdCR5-GFP. 293-cTA-CR5-GFP cells were generated
by transduction of 293cTA cells with lenti-CR5-GFP. Four
cell pools thus generated were analyzed by flow cytometry
to identify those that had 5–20% of GFP positive cells (to
assure one copy of integrated lentivirus genome per cell).
The selected pool was enriched for GFP+ cells by subse-
quent GFP positive cell sorting using a Coulter EPICS™ -
ESP cell sorter (Beckman-Coulter, Fl) using the same filter
set as described earlier. The final percentage of GFP+ cells
in the pool was 74%.
293-CR5-LacZ were generated by transfecting 1 × 106 293
cells with 4 µg of pAdCR5LacZ-neo using 8 µl of PEI rea-
gent. G418 (400 µg/ml) was added to the growth medium
48 h after the transfection to select a pool of G418-resist-
ant cells. Individual clones were isolated from this pool by
the method of limiting dilution and verified by infection
with AdCMV-cTA (see below).
293rcTA and 293CymR-rcTA
Cell lines stably expressing the rcTA, either under the con-
trol of a constitutive promoter (CMV5) or under an induc-
ible promoter (CMV5-CuO) were generated by
transducing the parental cells 293 and 293CymR with a
lentiviral vector lenti-CMV5-CuO-rcTA. The 293rcTA and
293CymR-rcTA pools were sub-cloned by limiting dilu-
tion. 293rcTA-CR5-SEAP-IRES-GFP and 293CymR-rcTA-
CR5-SEAP-IRES-GFP pools were generated by transduc-
ing 293rcTAclone #40 and 293CymR-rcTAclone #18 with
lenti-CR5-SEAP-IRES-GFP. The transduction was repeated
twice at 24 h intervals to maximize the number of cells
transduced.
Virus production and infection
Recombinant AdVs were generated by in vivo homologous
recombination between overlapping sequences of linear-
ized transfer vectors (pAdCR5-GFP, pAdCMV5-CuO-LacZ
and pAdCMV5-cTA) and Ad5/∆ E1∆ E3 in 293 cells as
described in Massie et al. [29]. An initial screen for recom-
binants plaques was performed by visual examination for
GFP expression (AdCR5-GFP) or β-gal activity (AdCMV5-
CuO-LacZ). Transgene expression was verified by western
analysis and activity was confirmed by co-infecting
293CR5LacZ (AdCMV5-cTA).
Lentivirus production: We have established a stable 293SF
cell line (adapted to serum-free culture) expressing both
the cumate repressor (CymR) and the reverse tetracycline
transactivator (rtTA) for tight regulation of the packaging
elements (293SF-PacLV). We co-transfected all packaging
plasmids in one shot with Rev and VSV-G being doubly
regulated. With the best clones generated, we obtained tit-
ers equal or greater than what is generated by transient
transfection of the packaging constructs (> 5X10E6 trans-
ducing units/ml) (Broussau et al. manuscript in prepara-
tion). 293SF-PacLV cells (clone #16–22) were seeded in
two 6 well plates at 0.75 × 106 cells per well in complete
H-SFM [Hybridoma-SFM (H-SFM, Invitrogen, Grand
Island, NY) supplemented with 0.1% Pluronic F-68 and
1% fetal bovine serum (FBS)]. The next day, media was
changed 2 hours prior to transfection. 3 µg of plasmid
(pRRL.cppt.CR5-GFP.WPRE, pRRL.cppt.CR5-SEAP-IRES-
GFP.WPRE, pRRL.cppt.CMV5-CuO-rcTA.WPRE) wasBMC Biotechnology 2006, 6:43 http://www.biomedcentral.com/1472-6750/6/43
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diluted in 100 µl of complete H-SFM without FBS and
mixed with 6 µg of PEI (preparation for one well). This
DNA/PEI complex was incubated at room temperature for
15 min before being added to the cells. The cell media was
changed 4 hours post-transfection with 2 ml per well of
complete H-SFM supplemented with 50 µg/ml cumate
and 1 µg/ml doxycycline to induce packaging elements for
lentivirus production. The supernatant was harvested 48 h
post-transfection, filtered at 0.45 µm and stored at -80°C.
Viral infections
Adenoviral infection
Cells were infected with the relevant viruses at a multiplic-
ity of infection (MOI) of 10. Forty-eight hours post-infec-
tion, reporter gene expression levels were measured. For
vectors with GFP as a reporter, total GFP fluorescence was
measured by an EPICS™XL-flow cytofluorometer (Beck-
man Coulter). The fluorescence index was calculated by
multiplying the percentage of positive cells by the mean
fluorescence value. For viruses with LacZ as a reporter, β-
galactosidase activity was measured as described above.
Lentiviral infection
The day before transduction, cells were seeded in a 12 well
plate at 0.14 × 106 cells per well. Dilutions were prepared
with 4 different amounts of the previously produced len-
tivirus: 250 µl, 166 µl, 50 µl and 16.6 µl diluted in Dul-
becco's Modified Eagle Medium (DMEM) supplemented
with 5% FBS for a total transduction volume of 500 µl
supplemented with 8 µg of polybrene. The virus/poly-
brene preparations were pre-incubated 30 min at 37°C
before adding to the cells and transductions were carried
out overnight at 37°C. The media was changed for fresh
DMEM followed by additional 48 h incubation at 37°C.
Mutagenesis of CymR
The PCR-based random mutagenesis of CymR was carried
out using GeneMorph™ PCR Mutagenesis Kit (Stratagene,
La Jolla, CA) according to the manufacturer's instructions.
Briefly, the plasmid pAdCMV5cTA was used as a template
for CymR mutations and the PCR was performed with the
primers 5'-TCCACTTTGCCTTTCTCTCC (forward primer)
and 5'-GTTTTTCGTACGCGC GCGGCTGTACG (reverse
primer) under conditions which would lead to frequent
misincorporation of nucleotides. A total of three groups
with different degrees of nucleotide misincorporation
ranging from 0–3 mismatches per kb to 7–13 mis-
matches/kb were generated. All three groups were
digested with BglII and NotI and ligated to the corre-
sponding restricted pAd-PS-CMVcTA-IRES-GFP to substi-
tute the wild-type CymR for the mutagenized ones. In
order to optimize the diversity of the CymR mutations,
electrophoretic transformation with E. coli Dh 5α was car-
ried out and maxi prepared DNA was ready for further use.
Generation of CymR mutant recombinant adenovirus libraries with 
positive selection
The adenovirus positive selection system has been
described previously (30). 293A cells were plated in 100
mm dish one day before the infection with modified ade-
novirus Ad5- PS at a MOI of 10-2. 5 h later, 10 µg DNA of
linearized pAd-PS-CMV-mut-cTA-IRES-GFP plasmid and
20 ul of PEI were added to the 100 mm dish of infected
293A cells to generate recombinant Ad5-PS-CMV-mut-
cTA-IRES-GFP libraries. 3 days later, when 90% of the cell
population was positive for GFP expression, cells were
harvested and subjected to 3 freeze-thaw cycles to release
the recombinant viruses. The measurement of virus titers
was done by plaque assay (5).
Recombinant adenovirus library screening
293A-CR5-LacZ were plated in 100 mm dishes (5 × 106
per dish) and infected with 100–200 p.f.u./dish. After 6 hr
infection, cells were washed and 10 ml of 5% agarose was
added to each plate. After the appearance of plaques, to
determine β-gal activity, the plates were overlayed with 5
ml of 1% sea plaque agarose in DMEM supplemented
with 0.06% blue-gal in the presence or absence of 200 µg/
ml of inducer cumate. Plaques were screened for β-gal
activity in the presence of cumate. Positive plaques were
purified three times for further analysis.
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